TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Eyepoint, Inc.
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

EyePoint announced progress on its lead product DURAVYU (vorolanib intravitreal insert) with Phase 3 wet AMD trials on track for data readout beginning mid-2026 and Phase 3 DME program first patient dosing expected in Q1 2026. The company completed enrollment of over 900 patients across wet AMD trials in 7 months and has approximately $300 million in cash runway into Q4 2027.

Insights
OGN   neutral

Mentioned as a leading market company without specific growth or innovation details


EYPT   positive

Company achieved rapid enrollment milestones (900+ patients in 7 months), secured $172.5 million in funding, has strong cash runway through Q4 2027, and is positioned as potentially first-to-market among investigational sustained delivery programs for wet AMD with data expected mid-2026. Independent DSMC recommended continuation without protocol modifications, indicating positive safety profile.